Get started
Author

Maurizio Rainisio

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study
2001 · Richard N Channick, Gérald Simonneau, et al. · The Lancet · 1,541
Long-term intravenous epoprostenol infusion in primary pulmonary hypertension
2002 · Olivier Sitbon, Marc Humbert, et al. · Journal of the American College of Cardiology · 1,381
PDF
Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist
2004 · J. H. Korn, M. Mayes, et al. · Arthritis & Rheumatism · 726
Survival with first-line bosentan in patients with primary pulmonary hypertension
2005 · V. V. McLaughlin, O. Sitbon, et al. · European Respiratory Journal · 599
PDF
Effects of the oral endothelin-receptorantagonist bosentan on echocardiographicand doppler measures in patients with pulmonary arterial hypertension
2003 · Nazzareno Galiè, Alan L. Hinderliter, et al. · Journal of the American College of Cardiology · 378
PDF
Effects of Tezosentan on Symptoms and Clinical Outcomes in Patients With Acute Heart Failure
2007 · John J. V. McMurray, John R. Teerlink, et al. · JAMA · 359
PDF
Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study
2000 · G. Mastella, M. Rainisio, et al. · European Respiratory Journal · 241
PDF
Presence of cystic fibrosis‐related diabetes mellitus is tightly linked to poor lung function in patients with cystic fibrosis: Data from the European Epidemiologic Registry of Cystic Fibrosis
2001 · C. Koch, M. Rainisio, et al. · Pediatric Pulmonology · 221
Clinical trial design and new therapies for pulmonary arterial hypertension
2018 · Olivier Sitbon, Mardi Gomberg-Maitland, et al. · European Respiratory Journal · 203
PDF
European Epidemiologic Registry of Cystic Fibrosis (ERCF): Comparison of major disease manifestations between patients with different classes of mutations
2001 · C. Koch, H. Cuppens, et al. · Pediatric Pulmonology · 198
Factors associated with poor pulmonary function: cross-sectional analysis of data from the ERCF
2001 · J. Navarro, M. Rainisio, et al. · European Respiratory Journal · 169
PDF
Tezosentan in patients with acuteheart failure and acute coronary syndromes
2003 · Christopher M O’Connor, Wendy A Gattis, et al. · Journal of the American College of Cardiology · 142
PDF
New Trial Designs and Potential Therapies for Pulmonary Artery Hypertension
2013 · Mardi Gomberg-Maitland, Todd M. Bull, et al. · Journal of the American College of Cardiology · 134
PDF
Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure
2003 · Guillermo Torre-Amione, James B Young, et al. · Journal of the American College of Cardiology · 118
PDF
Clinical and Hemodynamic Effects of Bosentan Dose Optimization in Symptomatic Heart Failure Patients with Severe Systolic Dysfunction, Associated with Secondary Pulmonary Hypertension – A Multi-Center Randomized Study
2007 · Edo Kaluski, Gad Cotter, et al. · Cardiology · 110
Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a placebo-controlled study
2001 · R. Channick, D.B. Badesch, et al. · The Journal of Heart and Lung Transplantation · 110
Acute Heart Failure in the Elderly: Differences in Clinical Characteristics, Outcomes, and Prognostic Factors in the VERITAS Study
2015 · Marco Metra, Gad Cotter, et al. · Journal of Cardiac Failure · 87
A cross-sectional and prospective cohort study of the role of schools in the SARS-CoV-2 second wave in Italy
2021 · Sara Gandini, Maurizio Rainisio, et al. · The Lancet Regional Health - Europe · 86
Neurohormonal Activation in Acute Heart Failure: Results from VERITAS
2011 · Olga Milo-Cotter, Beth Cotter-Davison, et al. · Cardiology · 70
Tezosentan in patients with acute heart failure: Design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS)
2005 · John R. Teerlink, John J.V. McMurray, et al. · American Heart Journal · 70
The Hemodynamic and Neurohormonal Effects of Low Doses of Tezosentan (An Endothelin A/B Receptor Antagonist) in Patients with Acute Heart Failure
2004 · Gad Cotter, Edo Kaluski, et al. · European Journal of Heart Failure · 58
The detection of antibodies to recombinant interferon alfa-2a in human serum
1987 · U. Hennes, W. Jucker, et al. · Journal of Biological Standardization · 53
Predictors and Associations With Outcomes of Length of Hospital Stay in Patients With Acute Heart Failure: Results From VERITAS
2015 · Gad Cotter, Beth A. Davison, et al. · Journal of Cardiac Failure · 37
Complete results of the first randomized, placebo-controlled study of bosentan, a dual endothelin receptor antagonist, in pulmonary arterial hypertension
2002 · David B. Badesch, Frédéric Bodin, et al. · Current Therapeutic Research · 37
A Case-Controlled Study with Dornase Alfa to Evaluate Impact on Disease Progression over a 4-Year Period
2001 · Pallav L. Shah, Steven Conway, et al. · Respiration · 36
Works count: 48
Citation count: 7,332
H-index: 28
I10-index: 31
Year
Topic
Type